Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455848 | 0.86 | HPGD (1.00) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL2405061 | 0.81 | HDAC3 (0.57) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL2405065 | 0.81 | HDAC3 (0.57) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL3319514 | 0.80 | HSD11B1 (0.77) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL1548107 | 0.79 | SPHK2 (0.80) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL24424186 | 0.79 | HPGD (0.57) | HPGDKMT2AMEN1TSHRKDM4E | |
| SCHEMBL22002337 | 0.77 | DPP8 (0.58) | HPGDKMT2AMEN1ALDH1A1EPHX2 | |
| SCHEMBL25190275 | 0.77 | HPGD (0.81) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL3361385 | 0.76 | HPGD (0.58) | HPGDKMT2AMEN1CYP17A1CYP19A1 | |
| SCHEMBL3455073 | 0.76 | POLB (0.74) | HPGDKMT2AMEN1CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569250-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| EP-2247602-B1 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120295860-A1 | ORGANIC COMPOUNDS | HASSIEPEN ULRICH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-8252751-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-2247602-A2 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100256080-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| WO-2009068531-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| EP-1137635-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| EP-1137635-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6166063-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034241-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256080-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | HPGD 3655/4885KMT2A 2697/4885MEN1 2859/4885 |
| US-20120295860-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | HPGD 3678/4885KMT2A 2688/4885MEN1 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.